AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tranylcypromine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2715 | 155-09-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 48 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.44 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 1.326 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.253 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 23.335 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 9.795 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 34 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 51.500 | % | High | 1 |
| herg | hERG pIC50 | 4.457 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 8.017 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 16.943 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 42.230 | % | High | 1 |
| kinase-safety-class | ACVR2B,AKT2,AXL,BRAF,CAMK2B,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,IRAK4,ITK,MAPK12,NTRK2,PDK2,PDK4,PRKDC,TEK,TGFBR1 | 19 | |||
| kinase-selectivity-class | AKT1,AKT2,AKT3,EIF2AK3,PDK4,PRKG1 | 6 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 4.325 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 54.702 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 37.330 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.355 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 39.230 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 52.602 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 70.720 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 34.570 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 887.156 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 21, 1961 | FDA | COVIS PHARMA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypertensive crisis | 210.16 | 48.73 | 50 | 1384 | 17734 | 90609279 |
| Potentiating drug interaction | 168.42 | 48.73 | 34 | 1400 | 5628 | 90621385 |
| Labelled drug-food interaction medication error | 115.16 | 48.73 | 16 | 1418 | 264 | 90626749 |
| Drug interaction | 81.90 | 48.73 | 52 | 1382 | 276401 | 90350612 |
| Serotonin syndrome | 76.65 | 48.73 | 27 | 1407 | 37860 | 90589153 |
| Diet noncompliance | 70.07 | 48.73 | 11 | 1423 | 429 | 90626584 |
| Congenital central nervous system anomaly | 62.00 | 48.73 | 10 | 1424 | 464 | 90626549 |
| Food interaction | 58.47 | 48.73 | 11 | 1423 | 1253 | 90625760 |
| Atrioventricular septal defect | 57.55 | 48.73 | 9 | 1425 | 342 | 90626671 |
| Drug dose titration not performed | 57.12 | 48.73 | 10 | 1424 | 762 | 90626251 |
| Craniosynostosis | 55.78 | 48.73 | 8 | 1426 | 167 | 90626846 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Jaw clicking | 71.13 | 45.29 | 9 | 751 | 60 | 42620515 |
| Conversion disorder | 52.30 | 45.29 | 9 | 751 | 551 | 42620024 |
| Yawning | 49.30 | 45.29 | 9 | 751 | 773 | 42619802 |
| Illusion | 46.83 | 45.29 | 9 | 751 | 1020 | 42619555 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hypertensive crisis | 189.45 | 43.54 | 47 | 1379 | 24325 | 110563548 |
| Serotonin syndrome | 107.85 | 43.54 | 37 | 1389 | 59116 | 110528757 |
| Potentiating drug interaction | 98.13 | 43.54 | 24 | 1402 | 11619 | 110576254 |
| Drug interaction | 72.36 | 43.54 | 56 | 1370 | 500127 | 110087746 |
| Labelled drug-food interaction medication error | 72.18 | 43.54 | 10 | 1416 | 200 | 110587673 |
| Drug dose titration not performed | 69.34 | 43.54 | 12 | 1414 | 1053 | 110586820 |
| Food interaction | 67.03 | 43.54 | 13 | 1413 | 2139 | 110585734 |
| Contraindicated product administered | 62.16 | 43.54 | 39 | 1387 | 248228 | 110339645 |
| Neuroleptic malignant syndrome | 56.95 | 43.54 | 20 | 1406 | 34039 | 110553834 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06AF04 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Monoamine oxidase inhibitors, non-selective |
| FDA MoA | N0000000184 | Monoamine Oxidase Inhibitors |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| FDA EPC | N0000175744 | Monoamine Oxidase Inhibitor |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38623 | EC 1.4.3.4 (monoamine oxidase) inhibitor |
| CHEBI has role | CHEBI:50183 | P450 inhibitor |
| CHEBI has role | CHEBI:50514 | vasoconstrictor agent |
| CHEBI has role | CHEBI:131509 | EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor |
Related Drugs by ATC class:
N06AF Monoamine oxidase inhibitors, non-selective 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Major depressive disorder | indication | 370143000 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Alcoholism | contraindication | 7200002 | |
| Bipolar disorder | contraindication | 13746004 | DOID:3312 |
| Feeling agitated | contraindication | 24199005 | |
| Orthostatic hypotension | contraindication | 28651003 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Anxiety | contraindication | 48694002 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Schizophrenia | contraindication | 58214004 | DOID:5419 |
| Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Seizure disorder | contraindication | 128613002 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Angina pectoris | contraindication | 194828000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hypoglycemic disorder | contraindication | 237630007 | |
| Syncope | contraindication | 271594007 | |
| Pheochromocytoma | contraindication | 302835009 | |
| Myelogram | contraindication | 367401004 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Severe Headache Disorder | contraindication | ||
| Hypertensive Emergencies | contraindication | ||
| Frequent Headache Disorder | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.31 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | IC50 | 7.48 | CHEMBL | CHEMBL | |||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.23 | PDSP | |||||
| Sodium-dependent dopamine transporter | Transporter | Ki | 5.29 | PDSP | |||||
| Cytochrome P450 2A6 | Enzyme | Ki | 7.19 | WOMBAT-PK | |||||
| Amine oxidase [flavin-containing] A | Enzyme | IC50 | 6.62 | CHEMBL | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 5.30 | CHEMBL | |||||
| Cytochrome P450 2B6 | Enzyme | IC50 | 5.16 | CHEMBL | |||||
| Lysine-specific histone demethylase 1A | Enzyme | Ki | 4.60 | CHEMBL | |||||
| Lysine-specific histone demethylase 1B | Enzyme | IC50 | 4.46 | CHEMBL | |||||
| Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.23 | PDSP | |||||
| 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase | Enzyme | IC50 | 5.11 | CHEMBL | |||||
| Cationic trypsin | Enzyme | Ki | 4.88 | CHEMBL | |||||
| D(2) dopamine receptor | GPCR | Ki | 4.23 | CHEMBL | |||||
| Amine oxidase [flavin-containing] B | Enzyme | IC50 | 7.11 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | IC50 | 6.54 | CHEMBL | |||||
| D(3) dopamine receptor | GPCR | Ki | 4.89 | CHEMBL | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane other | Ki | 5.75 | CHEMBL | |||||
| Sigma intracellular receptor 2 | Membrane receptor | Ki | 5.21 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019953 | VUID |
| N0000148038 | NUI |
| D00826 | KEGG_DRUG |
| 13492-01-8 | SECONDARY_CAS_RN |
| 4018013 | VANDF |
| 4019953 | VANDF |
| C0040778 | UMLSCUI |
| CHEBI:9652 | CHEBI |
| 1LP | PDB_CHEM_ID |
| CHEMBL3989843 | ChEMBL_ID |
| 5530 | PUBCHEM_CID |
| DB00752 | DRUGBANK_ID |
| CHEMBL3989698 | ChEMBL_ID |
| D014191 | MESH_DESCRIPTOR_UI |
| 986 | INN_ID |
| 5281 | IUPHAR_LIGAND_ID |
| 3E3V44J4Z9 | UNII |
| 10734 | RXNORM |
| 4529 | MMSL |
| 5608 | MMSL |
| 84239 | MMSL |
| d00884 | MMSL |
| 001496 | NDDF |
| 004597 | NDDF |
| 372891006 | SNOMEDCT_US |
| 89092006 | SNOMEDCT_US |
| 89772006 | SNOMEDCT_US |
| CHEMBL1255743 | ChEMBL_ID |
| 1986-47-6 | SECONDARY_CAS_RN |
| 3E3V44J4Z9 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Tranylcypromine Sulfate | Human Prescription Drug Label | 1 | 0591-5590 | TABLET, FILM COATED | 10 mg | ORAL | NDA AUTHORIZED GENERIC | 27 sections |
| Tranylcypromine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-739 | TABLET | 10 mg | ORAL | ANDA | 28 sections |
| Tranylcypromine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43547-655 | TABLET | 10 mg | ORAL | ANDA | 30 sections |
| PARNATE | Human Prescription Drug Label | 1 | 59212-447 | TABLET, FILM COATED | 10 mg | ORAL | NDA | 27 sections |
| TRANYLCYPROMINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-176 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 25 sections |
| Tranylcypromine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4708 | TABLET | 10 mg | ORAL | ANDA | 29 sections |
| Tranylcypromine | Human Prescription Drug Label | 1 | 70954-538 | TABLET | 10 mg | ORAL | ANDA | 29 sections |